Capital award

Lead Research Organisation: University of Dundee
Department Name: College of Life Sciences

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50

publication icon
Emmerich CH (2013) Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. in Proceedings of the National Academy of Sciences of the United States of America

publication icon
O'Reilly JX (2013) Dissociable effects of surprise and model update in parietal and anterior cingulate cortex. in Proceedings of the National Academy of Sciences of the United States of America

 
Description Research projects
Amount £407,142 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 04/2012 
End 03/2015
 
Description SRM analysis of the phosphorylation status of protein kinases
Amount £87,262 (GBP)
Funding ID A853/0142 
Organisation MRC-Technology 
Sector Private
Country United Kingdom
Start 09/2013 
End 08/2014
 
Description Division of Signal Transduction Therapy Cell signalling consortium 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution We are developing mass spectrometry based methods that will improve the undertsanding of the effects of modulators on cell signalling which as a result of the basic research will support the drug development process
Collaborator Contribution Advice on the pathways of most interest to industry and where greatest benefit would be obtained
Impact Ongoing and too early for tangible outputs
Start Year 2012
 
Description Division of Signal Transduction Therapy Cell signalling consortium 
Organisation Boehringer Ingelheim
Country Germany 
Sector Private 
PI Contribution We are developing mass spectrometry based methods that will improve the undertsanding of the effects of modulators on cell signalling which as a result of the basic research will support the drug development process
Collaborator Contribution Advice on the pathways of most interest to industry and where greatest benefit would be obtained
Impact Ongoing and too early for tangible outputs
Start Year 2012
 
Description Division of Signal Transduction Therapy Cell signalling consortium 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution We are developing mass spectrometry based methods that will improve the undertsanding of the effects of modulators on cell signalling which as a result of the basic research will support the drug development process
Collaborator Contribution Advice on the pathways of most interest to industry and where greatest benefit would be obtained
Impact Ongoing and too early for tangible outputs
Start Year 2012
 
Description Division of Signal Transduction Therapy Cell signalling consortium 
Organisation Johnson & Johnson
Department Janssen Pharmaceuticals
Country United States 
Sector Private 
PI Contribution We are developing mass spectrometry based methods that will improve the undertsanding of the effects of modulators on cell signalling which as a result of the basic research will support the drug development process
Collaborator Contribution Advice on the pathways of most interest to industry and where greatest benefit would be obtained
Impact Ongoing and too early for tangible outputs
Start Year 2012
 
Description Division of Signal Transduction Therapy Cell signalling consortium 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution We are developing mass spectrometry based methods that will improve the undertsanding of the effects of modulators on cell signalling which as a result of the basic research will support the drug development process
Collaborator Contribution Advice on the pathways of most interest to industry and where greatest benefit would be obtained
Impact Ongoing and too early for tangible outputs
Start Year 2012
 
Description Division of Signal Transduction Therapy Cell signalling consortium 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution We are developing mass spectrometry based methods that will improve the undertsanding of the effects of modulators on cell signalling which as a result of the basic research will support the drug development process
Collaborator Contribution Advice on the pathways of most interest to industry and where greatest benefit would be obtained
Impact Ongoing and too early for tangible outputs
Start Year 2012